Neuropace, Inc. NPCE Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s cumulative cost basis?
- Neuropace, Inc. (NPCE) reported cumulative cost basis of $9.55M in Q1 2026.
- How has Neuropace, Inc.'s cumulative cost basis changed year-over-year?
- Neuropace, Inc.'s cumulative cost basis increased by 4.1% year-over-year, from $9.18M to $9.55M.
- What is the long-term trend for Neuropace, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s cumulative cost basis has grown at a -4.4% compound annual growth rate (CAGR), from $11.66M to $9.33M.